Terapia de mantenimiento con inhibidores de PARP en cáncer de ovario: Un nuevo concepto para aumentar la supervivencia en la enfermedad recurrente

23 / 40

Mirza MR, et al. IGCS 2018.
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0-3 months 3 months - 1 year 1-2 years 2-4 years
Niraparib
Placebo
Treatment arm
Number of patients on treatment, N (%)
0–3 months 3 months–1 year 1–2 years 2–4 years
Niraparib 367 (100.0%) 298 (81.2%) 143 (39.0%) 69 (18.8%)
Placebo 179 (100.0%) 145 (81.0%) 31 (17.3%) 10 (5.6%)
Maintenance with Niraparib in all comers
NOVA: Long-term benefit